Comparing of Infinity Pharmaceuticals Inc. (INFI) and ChemoCentryx Inc. (NASDAQ:CCXI)

Both Infinity Pharmaceuticals Inc. (NASDAQ:INFI) and ChemoCentryx Inc. (NASDAQ:CCXI) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Infinity Pharmaceuticals Inc. 22.00M 3.44 10.33M 1.25 1.01
ChemoCentryx Inc. 89.84M 6.03 12.47M 0.19 52.02

Table 1 shows the gross revenue, earnings per share and valuation for Infinity Pharmaceuticals Inc. and ChemoCentryx Inc. ChemoCentryx Inc. is observed to has lower earnings, but higher revenue than Infinity Pharmaceuticals Inc. The company that is more affordable between the two has a lower price-to-earnings ratio. Infinity Pharmaceuticals Inc. is thus currently the affordable of the two stocks because it has a lower price-to-earnings ratio.

Profitability

Table 2 shows us Infinity Pharmaceuticals Inc. and ChemoCentryx Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals Inc. -46.95% -20.8% -18.2%
ChemoCentryx Inc. 13.88% 32.2% 6.5%

Risk and Volatility

Infinity Pharmaceuticals Inc. is 156.00% more volatile than S&P 500 due to its 2.56 beta. ChemoCentryx Inc.’s 72.00% more volatile than S&P 500 which is a result of the 1.72 beta.

Liquidity

Infinity Pharmaceuticals Inc.’s Current Ratio is 10.7 while its Quick Ratio is 10.7. On the competitive side is, ChemoCentryx Inc. which has a 2.9 Current Ratio and a 2.9 Quick Ratio. Infinity Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to ChemoCentryx Inc.

Analyst Ratings

In next table is delivered Infinity Pharmaceuticals Inc. and ChemoCentryx Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Infinity Pharmaceuticals Inc. 1 1 1 2.33
ChemoCentryx Inc. 0 2 2 2.50

Infinity Pharmaceuticals Inc. has a consensus target price of $3, and a 125.56% upside potential. Meanwhile, ChemoCentryx Inc.’s consensus target price is $16.88, while its potential upside is 57.32%. Based on the results delivered earlier, Infinity Pharmaceuticals Inc. is looking more favorable than ChemoCentryx Inc., analysts opinion.

Insider and Institutional Ownership

Roughly 53.1% of Infinity Pharmaceuticals Inc. shares are held by institutional investors while 55.5% of ChemoCentryx Inc. are owned by institutional investors. 1.5% are Infinity Pharmaceuticals Inc.’s share held by insiders. Insiders Competitively, held 4.8% of ChemoCentryx Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Infinity Pharmaceuticals Inc. -5.26% -49.4% -42.2% -31.89% -36.36% -37.93%
ChemoCentryx Inc. -0.1% -16.33% -9.75% -15.2% 69.59% 68.74%

For the past year Infinity Pharmaceuticals Inc. had bearish trend while ChemoCentryx Inc. had bullish trend.

Summary

ChemoCentryx Inc. beats Infinity Pharmaceuticals Inc. on 12 of the 15 factors.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.